SecBot SecBot
6-K ·Filed May 18, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001654954-26-005038
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a major label expansion for Enhertu into the curative-intent early breast cancer setting, significantly expanding the addressable patient population. The DESTINY-Breast05 data showing a 53% risk reduction in invasive disease recurrence is practice-changing and supports NCCN Category 1 recommendation. Monitor for rapid adoption in the neoadjuvant and adjuvant settings, and watch for regulatory decisions in other countries under Project Orbis. The $155M milestone is manageable for AstraZeneca's $56B+ market cap.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$183.91
T+0 close · May 18, 2026 · via day close
Latest settled
−14.01%
T+60 · $158.14
Vs SPY
−18.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $183.91entry
  2. T+1 · 6mo ago +0.42%α +1.07% · $184.68
  3. T+5 · 6mo ago +1.74%α +0.12% · $187.11
  4. T+20 · 5mo ago −3.61%α −5.80% · $177.27
  5. T+60 · 3mo ago −14.01%α −18.59% · $158.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced FDA approval of Enhertu (trastuzumab deruxtecan) for two new indications in HER2-positive early breast cancer: neoadjuvant (pre-surgery) treatment based on DESTINY-Breast11 Phase III trial, and adjuvant (post-surgery) treatment based on DESTINY-Breast05 Phase III trial. This expands Enhertu into the curative-intent early-stage setting, reinforcing its role across the HER2-positive breast cancer treatment continuum. A $155 million milestone payment is due from AstraZeneca to Daiichi Sankyo following these approvals.

Key Facts

  • FDA approved Enhertu for neoadjuvant treatment of HER2-positive Stage II/III early breast cancer (DESTINY-Breast11).
  • FDA approved Enhertu for adjuvant treatment of HER2-positive early breast cancer with residual disease after neoadjuvant therapy (DESTINY-Breast05).
  • DESTINY-Breast11 showed pCR rate of 67.3% vs 56.3% for standard care (improvement of 11.2%, p=0.003).
  • DESTINY-Breast05 showed 53% reduction in risk of invasive disease recurrence or death vs T-DM1 (HR 0.47, p<0.0001); 92.4% vs 83.7% alive and free of invasive disease at 3 years.
  • AstraZeneca owes Daiichi Sankyo $155 million in milestone payments for these two US approvals.
  • Enhertu is now approved in the US across both early and metastatic HER2-positive breast cancer.
  • No new safety concerns identified; ILD/pneumonitis rates were 9.6% in Enhertu arm vs 1.6% in T-DM1 arm in DESTINY-Breast05, with two Grade 5 events.

Financial Impact

$155 million milestone payment due from AstraZeneca to Daiichi Sankyo; revenue potential from expanded early-stage patient population (US breast cancer incidence ~320,000/year, ~20% HER2-positive).

revenueoperating expenses

Risk Factors

  • ILD/pneumonitis safety signal persists (9.6% in adjuvant arm, including 2 Grade 5 deaths) which may limit adoption in some patients.
  • Competition from other HER2-directed therapies (e.g., T-DM1, pertuzumab) and potential pricing pressure.
  • Revenue recognition for US sales is by Daiichi Sankyo, not AstraZeneca; AstraZeneca's economics come from profit-sharing, not direct sales.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005038
Document: 0001654954-26-005038-index-headers.html0001654954-26-005038
Document: 0001654954-26-005038-index.html0001654954-26-005038
Document: 0001654954-26-005038.txt0001654954-26-005038

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026